Ralph V. Boccia, MD

home / authors / ralph-v-boccia-md

Ralph V. Boccia, MD, is the founder of The Center for Cancer and Blood Disorders and board-certified in medical oncology, hematology and internal medicine.

Articles

mCSPC: Incorporating Newer Therapies Into Practice

mCSPC: Incorporating Newer Therapies Into Practice

Ralph V. Boccia, MD
December 2nd 2020
AR-Targeted Therapy for mCSPC: Monitoring for Progression

AR-Targeted Therapy for mCSPC: Monitoring for Progression

Ralph V. Boccia, MD
December 2nd 2020
AR-Targeted Therapy for mCSPC: Adverse Events

AR-Targeted Therapy for mCSPC: Adverse Events

Ralph V. Boccia, MD
December 2nd 2020
The TITAN Trial in mCSPC

The TITAN Trial in mCSPC

Ralph V. Boccia, MD
December 2nd 2020
mCSPC: Patient Variables and Treatment Selection

mCSPC: Patient Variables and Treatment Selection

Ralph V. Boccia, MD
December 2nd 2020
Frontline Therapy for mCSPC

Frontline Therapy for mCSPC

Ralph V. Boccia, MD
December 2nd 2020
Case Impressions: 66-Year-Old Man With mCSPC

Case Impressions: 66-Year-Old Man With mCSPC

Ralph V. Boccia, MD
December 2nd 2020
A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer

A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer

Ralph V. Boccia, MD
December 2nd 2020

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis
Published: December 12th 2022 | Updated: December 24th 2024
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis
SEQUOIA Trial: Updates from ASH 2024
Published: December 21st 2024 | Updated: December 24th 2024
SEQUOIA Trial: Updates from ASH 2024
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
Published: December 20th 2024 | Updated: December 24th 2024
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: December 24th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL